Skip to main content
. 2018 May 29;32(3):281–291. doi: 10.1007/s40259-018-0284-3

Fig. 3.

Fig. 3

Mean scores for decision criteria for the appraisal of dupilumab (vs. placebo) by the advisory committee. Criteria 1–3, 7–8 and 12–13 were evaluated in absolute terms (with a score between 0 and 5), while the rest were evaluated in terms relative to placebo (with a score between – 5 and 5)